^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | epitinib (HMPL-813) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and Efficacy of Epitinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Open-Label Multicentre Dose-Expansion Phase Ib Study
Published date:
05/06/2022
Excerpt:
The objective response rate (ORR) was 53.6% (95% CI 33.9%-72.5%) in 120 mg group and 40.5% (25.6%-56.7%) in 160 mg group. The median duration of response in the 120 mg and 160 mg groups were 7.40 months (95% CI 3.70-7.40) and 9.10 months (6.50-12.00), respectively. The median progression-free survival were 7.40 months (95% CI 5.40-9.20) and 7.40 months (5.50-10.00), respectively....In patients with EGFR-mutant NSCLC with brain metastasis, epitinib was well tolerable with a promising efficacy.
DOI:
10.1016/j.cllc.2022.03.014
Trial ID:
